JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s ...
SALT LAKE CITY and SUNNYVALE, Calif., Oct. 21, 2024 /PRNewswire/ -- Recursion, a leading TechBio company decoding biology to radically improve lives, and Google Cloud today announced an expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback